This July 4th, we reflect on the values of liberty and innovation that inspire the entire ANI team. Across the USA, our diverse workforce collaborates across borders to advance our mission of “Serving Patient & Improving Lives.” As we celebrate America's independence, we're thankful for the freedoms and opportunities that fuel progress worldwide. To our US team, happy Independence Day, and to all our colleagues around the globe, thank you for your dedication! #July4th #pharmaceuticals #ANIP
ANI Pharmaceuticals, Inc.’s Post
More Relevant Posts
-
🔍💊 In a heated Senate hearing on February 8th, the CEOs of Bristol Myers Squibb, Johnson & Johnson, and Merck faced rigorous questioning from various United States senators regarding the exorbitant prices of prescription drugs in the US. The testimony unfolded as a clash between the imperative of funding innovation and the growing outcry over affordability and accessibility. #SenateHearing #PharmaCEOs #DrugPricing #HealthcareAccess #Pharmaceuticals #HealthcareIndustry #PolicyDebate #MedicalCosts #AffordableMedicine #PatientAdvocacy #PrescriptionDrugs #HealthPolicy #Senate #PublicHealth #MedicalCosts #PrescriptionCosts
To view or add a comment, sign in
-
“𝘐𝘵 𝘪𝘴 𝘨𝘳𝘦𝘢𝘵 𝘵𝘰 𝘴𝘦𝘦 𝘺𝘰𝘶 𝘵𝘢𝘭𝘬 𝘢𝘣𝘰𝘶𝘵 𝘰𝘶𝘳 𝘤𝘶𝘳𝘳𝘦𝘯𝘵 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴, 𝘢𝘯𝘥 𝘩𝘰𝘸 𝘸𝘦 𝘤𝘢𝘯 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘸𝘩𝘢𝘵 𝘸𝘦 𝘥𝘰 𝘵𝘰𝘥𝘢𝘺. 𝘞𝘩𝘪𝘭𝘦 𝘢𝘭𝘭 𝘵𝘩𝘦 𝘵𝘢𝘭𝘬 𝘢𝘣𝘰𝘶𝘵 𝘥𝘢𝘵𝘢 𝘪𝘴 𝘨𝘳𝘦𝘢𝘵, 𝘸𝘦 𝘴𝘵𝘪𝘭𝘭 𝘩𝘢𝘷𝘦 𝘵𝘰 𝘶𝘴𝘦 𝘥𝘰𝘤𝘶𝘮𝘦𝘯𝘵𝘴 𝘧𝘰𝘳 𝘢𝘭𝘮𝘰𝘴𝘵 𝘦𝘷𝘦𝘳𝘺𝘵𝘩𝘪𝘯𝘨 𝘸𝘦 𝘥𝘰 𝘵𝘰𝘥𝘢𝘺.“ That's the feedback my colleague Geert Van Peteghem received after his presentation at the GPRAS conference last month in Brussels. Our upcoming webinar is going to focus on solving the challenges you face today: 𝐇𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐦𝐚𝐤𝐞 𝐬𝐮𝐫𝐞 𝐲𝐨𝐮 𝐬𝐩𝐞𝐧𝐝 𝐚𝐬 𝐥𝐢𝐭𝐭𝐥𝐞 𝐭𝐢𝐦𝐞 𝐚𝐬 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐰𝐡𝐞𝐧 𝐩𝐫𝐞𝐩𝐚𝐫𝐢𝐧𝐠 𝐜𝐨𝐫𝐫𝐞𝐜𝐭𝐥𝐲-𝐟𝐨𝐫𝐦𝐚𝐭𝐭𝐞𝐝, 𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐭 𝐏𝐃𝐅𝐬 𝐟𝐨𝐫 𝐠𝐥𝐨𝐛𝐚𝐥 𝐬𝐮𝐛𝐦𝐢𝐬𝐬𝐢𝐨𝐧𝐬? You will find the answer in one of our sessions on December 14. The link to both sessions is in the comments. See you there! #regulatoryoperations #pharmaceuticals #regulatorysubmissions #PDF #automation
To view or add a comment, sign in
-
💢𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗟𝗲𝗮𝗱𝗲𝗿 ❁ Director Clinical Research Operations ❁ Oncology & Rare Diseases ❁ Strategic & Operational Oversight ❁ Execution & Delivery ❁ Helping Small Teams Make a Big Impact
🌟 Virtually attending the Regulatory Education for Industry (REdI) Annual Conference 2024: Innovation in Medical Product Development - May 29 - 30 🌟 This event is a great opportunity to learn directly from the FDA’s experts in drugs, devices, and biologics. I'm looking forward to strengthening my foundational knowledge of the FDA’s regulatory requirements and gaining insights into the latest industry activities. This conference is a great chance to stay ahead in our ever-evolving industry and ensure that we continue to innovate safely and effectively. https://lnkd.in/g3pe_FCB Who else is attending? #REdI2024 #MedicalInnovation #FDA #RegulatoryAffairs #ClinoptimaSolutions
To view or add a comment, sign in
-
Stay ahead of the game in the fast-paced world of #pharmaceuticals with #TheMicro Newsletter. We bring you thoughtfully curated and actionable information to fuel your success. Whether you're looking to stay updated on the latest trends or seeking strategies to enhance your operations, The Micro Newsletter has got you covered. https://okt.to/iePO20
To view or add a comment, sign in
-
Learn how we have helped pharma/biotech companies address their clinical supply chain challenges...see you there!!!
Join us at the Clinical Trial Supply East Coast Conference, October 11-12, in King of Prussia, PA! Discover how we can enhance your clinical supply chain and get a chance to win an Apple Watch 9! Can't attend? No worries! Reach out to us at info@relevancelab.com to schedule a meeting at your convenience. Let's conquer common challenges together and accelerate your pharma supply chain management success. Book a meeting: https://lnkd.in/gNFJGVhP EastCoast Conference #ClinicalSupplyChain #Pharmaceuticals #HealthcareTech #Conference #AppleWatch #SupplyChainSolutions #RelevanceLab #WinBig
To view or add a comment, sign in
-
CEO, Board Member, Biotechnology Pharmaceutical Consultant, Speaker, Author, Governance, Risk Management, Audit & Compliance, Clinical Product Development, Public, Privately Held, Family-Owned
New Regulatory changes in the new year- EU Medical Device regulation change Significant change in EU because there is an update of 2016 MEDDEV 2.7/1, rev. 4, which is a guideline for medical devices to align with other EU device regulation changes. The timeline is to phase in changes with all change phased in by 2024. What is changing in Stage 1: 1. Clarify terms used in the EU MDR 2. Clarify conduct clinical evaluations and use of data from diverse types of clinical trials What is changing in Stage 2: 1. Clarity on clinical evaluation process and clinical evaluation landscape Add this to your stack of EU changes on medical device guidance over the past few years... #biotechnology #pharmaceutical #compliance #riskmanagement #medicaldevice
To view or add a comment, sign in
-
"It's You Vs You": A Call to Action Success in our field is about facing challenges head-on, including the ones we set for ourselves. This principle reminds us that our biggest growth comes from conquering personal obstacles. Share your strategies for overcoming self-doubt and pushing beyond your limits. #professionalgrowth #pharmaceuticals #regulatory #pharma
To view or add a comment, sign in
-
In The Recorder, my colleagues Teresa Bonder and Jamie George unpack how companies can navigate #pharmaceutical collaboration disputes, how they can address future pain points, and what they can do to protect themselves when a collaboration ends in conflict. #lifesciences
6 Ways To Navigate Pharmaceutical Partnerships and Disputes
alston.smh.re
To view or add a comment, sign in
-
Yesterday, 10 April, the European Parliament adopted their reports on the revision of the #GeneralPharmaceuticalLegislation (#GPL). The European Parliament supported all the compromise amendments (Directive and Regulation) proposed by the ENVI Committee (Environment, Public Health and Food Safety). On many topics, including #RegulatoryDataProtection, #OrphanMarketExclusivity and the #access proposal, Parliament reports are an improvement compared to the Commission’s proposal. However, there are still questions on the incentive framework, #MedicineShortages and the #EnvironmentalRiskAssessment (ERA). Discussions are still taking place in the Council and then trilogue negotiations can begin. It is not anticipated that the legislation will go into effect until 2028. Thanks EUCOPE - European Confederation of Pharmaceutical Entrepreneurs to always keep us informed and also inform others about the requirements and practical implications on smaller #raredisease companies like AOP Health. #EUPharamaPackage #importantvote #needs #changeahead
🗞 Less than a year since the European Commission proposal, the European Parliament adopted the reports on the revision of the #pharmaceutical legislation yesterday (10 April). In line with the #ENVI proposals, the European Parliament recognised the need to strengthen the #incentive framework for #innovation. 📍 A forward-looking #regulatory system, a holistic approach to #access, and more predictable incentives are some of the elements addressed by the Parliament. However, uncertainties remain about additional obligations and requirements that may be particularly burdensome for #SMEs. ✒ Our Secretary General, Alexander Natz, urged caution in the implementation of these policies, balancing innovation with rapid and safe access to new #therapies for #patients. 👉 Read EUCOPE's press release: https://lnkd.in/dRXknvvE
To view or add a comment, sign in
-
🗞 Less than a year since the European Commission proposal, the European Parliament adopted the reports on the revision of the #pharmaceutical legislation yesterday (10 April). In line with the #ENVI proposals, the European Parliament recognised the need to strengthen the #incentive framework for #innovation. 📍 A forward-looking #regulatory system, a holistic approach to #access, and more predictable incentives are some of the elements addressed by the Parliament. However, uncertainties remain about additional obligations and requirements that may be particularly burdensome for #SMEs. ✒ Our Secretary General, Alexander Natz, urged caution in the implementation of these policies, balancing innovation with rapid and safe access to new #therapies for #patients. 👉 Read EUCOPE's press release: https://lnkd.in/dRXknvvE
To view or add a comment, sign in
18,654 followers